Regulatory & Compliance

Kylo-11 siRNA Results Set New Standard for Heart Disease Trials
Research & Development Kylo-11 siRNA Results Set New Standard for Heart Disease Trials

Regulatory bodies like the FDA will likely demand more detailed pharmacokinetic characterization of tissue distribution following the prolonged activity seen with Kylo-11. The cardiovascular research community is currently absorbing the profound implications of the Phase 1 clinical trial results

Is India Prepared for the Evolving Threat of Bioterrorism?
Management & Regulatory Is India Prepared for the Evolving Threat of Bioterrorism?

Although India maintains a robust network of over 150 viral research laboratories, the architecture is primarily designed for public health rather than forensic attribution. This distinction is becoming increasingly vital as the national security landscape shifts away from large-scale insurgencies

How Will Fortrea’s Latest Acquisition Impact Your Clinical Trials?
Management & Regulatory How Will Fortrea’s Latest Acquisition Impact Your Clinical Trials?

Phase I Pharmacokinetic studies cannot reach their primary endpoints until bioanalytical data is confirmed as valid across the newly integrated organizational framework. The clinical research landscape shifted significantly with the announcement of Fortrea’s acquisition of Worldwide Clinical

How Can You Avoid the MyChart Phishing Scam Targeting Ohio?
Tech & Innovation How Can You Avoid the MyChart Phishing Scam Targeting Ohio?

Criminals are leveraging the trust associated with digital medical platforms to execute sophisticated identity theft and financial fraud against the elderly. In recent months, Ohio has seen a sharp increase in fraudulent activity specifically targeting patients using the MyChart application, which

Piramal Pharma Highlights ESG Success in New Sustainability Report
Management & Regulatory Piramal Pharma Highlights ESG Success in New Sustainability Report

Piramal Pharma is currently evaluating 38% of its critical suppliers against strict environmental, social, and governance criteria to ensure sustainability throughout the entire value chain. This initiative represents a fundamental shift in how the pharmaceutical industry approaches procurement,

NIH Proposes New Oversight Rules for All Lab Biohazards
Biotech & Bioprocessing NIH Proposes New Oversight Rules for All Lab Biohazards

Institutions receiving federal funding will soon face mandatory oversight for all biohazards, including toxins and prions, regardless of whether genetic modification is involved. This sweeping proposal from the National Institutes of Health represents a fundamental shift in how biological research

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later